Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Biliary Tract Diseases

ClinicalTrials.gov lists 2,238 trials for Biliary Tract Diseases or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 40.

MeSH D001660 Digestive System Diseases C06
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 184 Phase 1/2 Phase 1/2 96 Phase 2 Phase 2 431 Phase 2/3 Phase 2/3 48 Phase 3 Phase 3 149 Phase 4 Phase 4 101 Not applicable Not applicable 629 Observational Observational 583 Phase 1 Phase 1 184 Phase 1/2 Phase 1/2 96 Phase 2 Phase 2 431 Phase 2/3 Phase 2/3 48 Phase 3 Phase 3 149 Phase 4 Phase 4 101 Not applicable Not applicable 629 Observational Observational 583

Trials per phase

2 more sections with rows

58 of the 2,238 trials are tagged with Biliary Tract Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Biliary Tract Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Biliary Tract Diseases trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 168

1991: 1 trials (Observational 1) 1992: 1 trials (Phase 3 1) 1994: 4 trials (Phase 3 2, Phase 2 1, Phase 1 1) 1995: 2 trials (Observational 1, Phase 2 1) 1996: 1 trials (Observational 1) 1997: 8 trials (Observational 2, Not applicable 2, Phase 1 4) 1998: 11 trials (Not applicable 1, Phase 3 1, Phase 2 3, Phase 1 6) 1999: 9 trials (Observational 2, Phase 2 5, Phase 1 2) 2000: 15 trials (Observational 5, Not applicable 2, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 4) 2001: 11 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2002: 16 trials (Observational 3, Phase 4 1, Phase 2/3 1, Phase 2 9, Phase 1 2) 2003: 25 trials (Observational 4, Not applicable 7, Phase 2 8, Phase 1/2 2, Phase 1 4) 2004: 24 trials (Observational 7, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2005: 28 trials (Observational 7, Not applicable 5, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1 2) 2006: 41 trials (Observational 10, Not applicable 9, Phase 4 2, Phase 3 7, Phase 2/3 4, Phase 2 7, Phase 1 2) 2007: 40 trials (Observational 11, Not applicable 10, Phase 3 4, Phase 2 8, Phase 1/2 1, Phase 1 6) 2008: 48 trials (Observational 15, Not applicable 13, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 5) 2009: 61 trials (Observational 7, Not applicable 19, Phase 4 8, Phase 3 8, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 5) 2010: 63 trials (Observational 14, Not applicable 18, Phase 4 6, Phase 3 4, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 5) 2011: 61 trials (Observational 16, Not applicable 21, Phase 4 5, Phase 3 5, Phase 2/3 1, Phase 2 7, Phase 1/2 2, Phase 1 4) 2012: 59 trials (Observational 17, Not applicable 20, Phase 4 5, Phase 3 4, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 6) 2013: 78 trials (Observational 18, Not applicable 22, Phase 4 9, Phase 3 1, Phase 2 17, Phase 1/2 3, Phase 1 8) 2014: 76 trials (Observational 13, Not applicable 21, Phase 4 10, Phase 3 7, Phase 2/3 1, Phase 2 21, Phase 1/2 1, Phase 1 2) 2015: 88 trials (Observational 21, Not applicable 29, Phase 4 4, Phase 3 2, Phase 2/3 2, Phase 2 20, Phase 1/2 1, Phase 1 9) 2016: 109 trials (Observational 26, Not applicable 39, Phase 4 5, Phase 3 11, Phase 2/3 1, Phase 2 16, Phase 1/2 5, Phase 1 6) 2017: 101 trials (Observational 31, Not applicable 25, Phase 4 4, Phase 3 2, Phase 2/3 2, Phase 2 22, Phase 1/2 5, Phase 1 10) 2018: 96 trials (Observational 25, Not applicable 25, Phase 4 2, Phase 3 10, Phase 2/3 2, Phase 2 22, Phase 1/2 5, Phase 1 5) 2019: 122 trials (Observational 26, Not applicable 44, Phase 3 8, Phase 2/3 2, Phase 2 25, Phase 1/2 6, Phase 1 11) 2020: 145 trials (Observational 54, Not applicable 40, Phase 4 4, Phase 3 7, Phase 2/3 1, Phase 2 26, Phase 1/2 8, Phase 1 5) 2021: 139 trials (Observational 37, Not applicable 43, Phase 4 6, Phase 3 10, Phase 2/3 2, Phase 2 25, Phase 1/2 6, Phase 1 10) 2022: 124 trials (Observational 44, Not applicable 36, Phase 4 1, Phase 3 2, Phase 2/3 5, Phase 2 21, Phase 1/2 9, Phase 1 6) 2023: 145 trials (Other 1, Observational 41, Not applicable 45, Phase 4 3, Phase 3 12, Phase 2/3 7, Phase 2 19, Phase 1/2 9, Phase 1 8) 2024: 168 trials (Observational 52, Not applicable 45, Phase 4 3, Phase 3 10, Phase 2/3 6, Phase 2 28, Phase 1/2 9, Phase 1 15) 2025: 143 trials (Observational 39, Not applicable 38, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 30, Phase 1/2 10, Phase 1 12)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 144
2025 143
2024 168
2023 145
2022 124
2021 139
2020 145
2019 122
2018 96
2017 101

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 160 trials starting in 2026 and about 160 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 229 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 1,197 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Biliary Tract Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 184
Phase 1/2 96
Phase 2 431
Phase 2/3 48
Phase 3 149
Phase 4 101
Not applicable 629
Observational 583
Expanded access 16
Unknown 1

How many Biliary Tract Diseases trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 121
Recruiting 325
Enrolling by invitation 12
Active, not recruiting 97
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Biliary Tract Diseases trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 40
Mirum Pharmaceuticals, Inc. 24
AstraZeneca 19
Gilead Sciences 17
Intercept Pharmaceuticals 14

Which drugs are being tested for Biliary Tract Diseases? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
"Capecitabine" 56
Ursodeoxycholic Acid 51
OXALIPLATIN 38
DURVALUMAB 32
PEMBROLIZUMAB 29

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 109
Cisplatin 1 76
Fluorouracile 37
OMEGAVEN 10%® 23
Bevacizumab 1 17

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Biliary Tract Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Cholangitis 374 49
Sepsis 306 69
Pyrexia 264 43
Abdominal pain 234 63
Pneumonia 197 49

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Biliary Tract Diseases? (172)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Impact of COVID-19 Infection on Pancreato-Biliary Diseases Requiring Endoscopic Retrograde Cholangiopancreatography. Digestive diseases and sciences 2024 Yes
Dual hypothermic oxygenated machine perfusion of the liver reduces post-transplant biliary complications: a retrospective cohort study. International journal of surgery (London, England) 2024 Yes
Risk factors and impact of early anastomotic biliary complications after liver transplantation: UK registry analysis. BJS open 2021 Yes
Primary Needle-Knife Fistulotomy Versus Conventional Cannulation Method in a High-Risk Cohort of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. The American journal of gastroenterology 2020 Yes
Prospective randomized trial of a new multibending versus conventional ultra-slim endoscope for peroral cholangioscopy without device or endoscope assistance (with video). Gastrointestinal endoscopy 2020 Yes

Showing 5 of 172 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages